Sort
10,766 grants matching “checkpoint inhibitor”
Cancer Biology Program
$72,334Ann Marie Pendergast · Duke University · P30 · FY2023 · CA
Cancer Biology Program
$72,334Ann Marie Pendergast · Duke University · P30 · FY2022 · CA
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response
$72,263Jamey P Weichert · University Of Wisconsin-Madison · P01 · FY2024 · CA
The changing neoantigen landscape and associated immune response during immune checkpoint blockade in recurrent glioblastoma: a pathway to personalized tumor immunotherapy
$72,230Christina Jackson · Johns Hopkins University · F32 · FY2019 · NS
Exploiting the HER3-PI3K/mTOR-Immune Axis to Design Precision Immune Oncology Therapy for Head & Neck Cancer
$72,230Robert Saddawi-Konefka · University Of California, San Diego · F32 · FY2020 · DE
Identification of Causal Antigens in Immune Checkpoint Inhibitor-Induced Myocarditis
$72,230Han Zhu · Stanford University · F32 · FY2019 · HL
Mechanisms of Tumor Derived Neutrophil Induced Apoptosis in Lymphocytes
$72,186A. McGarry Houghton · Fred Hutchinson Cancer Research Center · R01 · FY2021 · CA
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy Supplement
$72,104Zihai Li · Ohio State University · R01 · FY2023 · CA
Program 30: Neuro-Oncology
$72,080Charles Stiles · Dana-Farber Cancer Inst · P30 · FY2019 · CA
Novel focused ultrasound enhanced calreticulin-nanoparticle for immune primed melanoma immunotherapy
$72,048Ashish Ranjan · Oklahoma State University Stillwater · R37 · FY2023 · CA
Defining immune footprint in tumor microenvironment following high salt synergized inflammatory cytokine mediated breast cancer progression
$72,040Anil Shanker · Meharry Medical College · U54 · FY2018 · CA
Improvement of cellular immunotherapy during dysbiosis- Resubmission
$71,997Ruud P.m. Dings · Univ Of Arkansas For Med Scis · R01 · FY2024 · CA
Targeting polo-like kinase for therapy of small cell lung cancer
$71,915Taofeek K Owonikoko · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
Regulation of T cell activation and exhaustion by Tim-3
$71,888Lawrence P Kane · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · AI
Transposon control as a checkpoint during regeneration
$71,792Krista Marie Angileri · Cornell University · F32 · FY2023 · EY
Investigating conserved mechanisms that orchestrate the prophase to metaphase transition during meiosis I
$71,792Ian Wolff · Cornell University · F32 · FY2023 · HD
Mechanisms and therapeutic implications of temozolomide resistance in glioblastoma
$71,734Matthew McCord · Northwestern University At Chicago · F32 · FY2022 · CA
Production of Interferon Gamma by Regulatory T Cells Mediates Response to Immunotherapy
$71,734Angela Marie Gocher-Demske · University Of Pittsburgh At Pittsburgh · F32 · FY2022 · CA
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
$71,648Jin Wang · Baylor College Of Medicine · R01 · FY2024 · CA
Role of melanoma-PD-1 in cancer progression: diversity supplement
$71,600Tobias Schatton · Brigham And Women'S Hospital · R01 · FY2018 · CA
Covalent PD1 Antagonists: Discovery of Protein-Protein Interaction (PPI) Inhibitors in Cancer Immunotherapy
$71,467Stephane P Roche · Florida Atlantic University · R03 · FY2025 · CA
Tumor Immunology
$71,440Antoni Ribas · University Of California Los Angeles · P30 · FY2020 · CA
Investigating concurrent Ras-pathway inhibition to optimize response to anti-PD-1 therapy in NRAS-mutant melanoma
$71,430Caroline Nebhan · Vanderbilt University Medical Center · F32 · FY2020 · CA
Targeting MCL-1 dependent apoptotic vulnerability of KRAS-LKB1 NSCLC
$71,430Chendi Li · Massachusetts General Hospital · F32 · FY2020 · CA
Role of type 2 immune response in pancreatic cancer tumorigenesis
$71,398Prasenjit Dey · Roswell Park Cancer Institute Corp · R01 · FY2025 · CA